236 related articles for article (PubMed ID: 34789453)
1. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles.
Saper VE; Ombrello MJ; Tremoulet AH; Montero-Martin G; Prahalad S; Canna S; Shimizu C; Deutsch G; Tan SY; Remmers EF; Monos D; Hahn T; Phadke OK; Cassidy E; Ferguson I; Mallajosyula V; Xu J; Rosa Duque JS; Chua GT; Ghosh D; Szymanski AM; Rubin D; Burns JC; Tian L; Fernandez-Vina MA; Mellins ED; Hollenbach JA; ;
Ann Rheum Dis; 2022 Mar; 81(3):406-415. PubMed ID: 34789453
[TBL] [Abstract][Full Text] [Related]
2. Effects of HLA-DRB1 alleles on susceptibility and clinical manifestations in Japanese patients with adult onset Still's disease.
Asano T; Furukawa H; Sato S; Yashiro M; Kobayashi H; Watanabe H; Suzuki E; Ito T; Ubara Y; Kobayashi D; Iwanaga N; Izumi Y; Fujikawa K; Yamasaki S; Nakamura T; Koga T; Shimizu T; Umeda M; Nonaka F; Yasunami M; Ueki Y; Eguchi K; Tsuchiya N; Tohma S; Yoshiura KI; Ohira H; Kawakami A; Migita K
Arthritis Res Ther; 2017 Sep; 19(1):199. PubMed ID: 28899403
[TBL] [Abstract][Full Text] [Related]
3. HLA-DQB1 DPB1 alleles in Japanese patients with adult-onset Still's disease.
Fujita Y; Furukawa H; Asano T; Sato S; Yashiro Furuya M; Kobayashi H; Watanabe H; Suzuki E; Koga T; Shimizu T; Ueki Y; Eguchi K; Tsuchiya N; Kawakami A; Migita K
Mod Rheumatol; 2019 Sep; 29(5):843-847. PubMed ID: 30136608
[No Abstract] [Full Text] [Related]
4. Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease.
Fujii T; Nojima T; Yasuoka H; Satoh S; Nakamura K; Kuwana M; Suwa A; Hirakata M; Mimori T
Rheumatology (Oxford); 2001 Dec; 40(12):1398-404. PubMed ID: 11752512
[TBL] [Abstract][Full Text] [Related]
5. The amino acid variants in HLA II molecules explain the major association with adult-onset Still's disease in the Han Chinese population.
Teng JL; Chen X; Chen J; Zeng T; He L; Li M; Luo CN; Liu S; Ding TT; Yimaiti K; Li X; Ding Y; Cheng XB; Zhou J; Ye JN; Ji J; Su YT; Shi H; Sun Y; Gao C; Hu QY; Chi HH; Yuan X; Zhou ZC; Wang D; Wang K; Feng D; Li C; Sun Y; Niu Y; Xu X; Chen LJ; Xu J; Wu LJ; Zhou Z; Pan D; Niu H; Yang CD; Yongyong Shi ; Li Z; Liu HL
J Autoimmun; 2021 Jan; 116():102562. PubMed ID: 33168359
[TBL] [Abstract][Full Text] [Related]
6. Association between HLA-DR B1 and clinical features of adult onset Still's disease in Korea.
Joung CI; Lee HS; Lee SW; Kim CG; Song YH; Jun JB; Chung WT; Choe JY; Kim TG; Yoo DH
Clin Exp Rheumatol; 2003; 21(4):489-92. PubMed ID: 12942703
[TBL] [Abstract][Full Text] [Related]
7. Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.
Colafrancesco S; Manara M; Bortoluzzi A; Serban T; Bianchi G; Cantarini L; Ciccia F; Dagna L; Govoni M; Montecucco C; Priori R; Ravelli A; Sfriso P; Sinigaglia L;
Arthritis Res Ther; 2019 Dec; 21(1):275. PubMed ID: 31829244
[TBL] [Abstract][Full Text] [Related]
8. Anakinra in children and adults with Still's disease.
Vastert SJ; Jamilloux Y; Quartier P; Ohlman S; Osterling Koskinen L; Kullenberg T; Franck-Larsson K; Fautrel B; de Benedetti F
Rheumatology (Oxford); 2019 Nov; 58(Suppl 6):vi9-vi22. PubMed ID: 31769856
[TBL] [Abstract][Full Text] [Related]
9. Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: a case report.
Guignard S; Dien G; Dougados M
Clin Exp Rheumatol; 2007; 25(5):758-9. PubMed ID: 18078628
[TBL] [Abstract][Full Text] [Related]
10. Adult-onset Still's disease.
Gerfaud-Valentin M; Jamilloux Y; Iwaz J; Sève P
Autoimmun Rev; 2014 Jul; 13(7):708-22. PubMed ID: 24657513
[TBL] [Abstract][Full Text] [Related]
11. Interluekin-6 inhibitors for the treatment of adult-onset Still's disease.
Kaneko Y
Mod Rheumatol; 2022 Jan; 32(1):12-15. PubMed ID: 34894252
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study.
Laskari K; Tzioufas AG; Moutsopoulos HM
Arthritis Res Ther; 2011 Jun; 13(3):R91. PubMed ID: 21682863
[TBL] [Abstract][Full Text] [Related]
13. [Severe hepatitis in a patient with adult-onset Still's disease treated with anakinra].
Diallo A; Mekinian A; Boukari L; Mouas H; Zamy M; Nahon P; Gérin M; Fain O
Rev Med Interne; 2013 Mar; 34(3):168-70. PubMed ID: 23182291
[TBL] [Abstract][Full Text] [Related]
14. IL-1 Trap rilonacept in refractory adult onset Still's disease.
Petryna O; Cush JJ; Efthimiou P
Ann Rheum Dis; 2012 Dec; 71(12):2056-7. PubMed ID: 22679302
[No Abstract] [Full Text] [Related]
15. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.
Gabay C; Fautrel B; Rech J; Spertini F; Feist E; Kötter I; Hachulla E; Morel J; Schaeverbeke T; Hamidou MA; Martin T; Hellmich B; Lamprecht P; Schulze-Koops H; Courvoisier DS; Sleight A; Schiffrin EJ
Ann Rheum Dis; 2018 Jun; 77(6):840-847. PubMed ID: 29472362
[TBL] [Abstract][Full Text] [Related]
16. JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
Gillard L; Pouchot J; Cohen-Aubart F; Koné-Paut I; Mouterde G; Michaud M; Reumaux H; Savey L; Belot A; Fautrel B; Mitrovic S
Rheumatology (Oxford); 2023 Apr; 62(4):1594-1604. PubMed ID: 35920788
[TBL] [Abstract][Full Text] [Related]
17. Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy?
Efthimiou P; Kontzias A; Ward CM; Ogden NS
Nat Clin Pract Rheumatol; 2007 Jun; 3(6):328-35. PubMed ID: 17538564
[TBL] [Abstract][Full Text] [Related]
18. Rapid responses to anakinra in patients with refractory adult-onset Still's disease.
Fitzgerald AA; Leclercq SA; Yan A; Homik JE; Dinarello CA
Arthritis Rheum; 2005 Jun; 52(6):1794-803. PubMed ID: 15934079
[TBL] [Abstract][Full Text] [Related]
19. Treatment of refractory adult onset Still's disease with tocilizumab-a single centre experience and literature review.
Reihl Crnogaj M; Čubelić D; Babić A; Mayer M; Anić B
Rheumatol Int; 2020 Aug; 40(8):1317-1325. PubMed ID: 32506202
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still's disease.
Kaneko Y; Takeuchi T
Expert Opin Biol Ther; 2022 Jan; 22(1):79-85. PubMed ID: 34126828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
